PUBLISHER: The Business Research Company | PRODUCT CODE: 1458738
PUBLISHER: The Business Research Company | PRODUCT CODE: 1458738
Sarcopenia treatment encompasses medical interventions and lifestyle strategies tailored to counteract age-related muscle loss, aiming to preserve or enhance skeletal muscle mass and function. The goal of treatment is to mitigate age-related muscle decline, bolster muscle strength, and improve overall physical function and mobility.
The main types of sarcopenia treatments include protein supplements, vitamin B12 supplements, vitamin D and calcium supplements, and others. Protein supplements, available in forms such as bars, powders, or shakes derived from whey, plant, or meat sources, are utilized for both primary and secondary sarcopenia treatment and can be administered orally, parenterally, or enterally. These supplements are distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies.
The sarcopenia treatment market research report is one of a series of new reports from The Business Research Company that provides sarcopenia treatment market statistics, including sarcopenia treatment industry global market size, regional shares, competitors with a sarcopenia treatment market share, detailed sarcopenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sarcopenia treatment industry. This sarcopenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.30 billion in 2023 to $3.52 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historical period can be attributed to several factors, including the aging population, increased awareness and diagnosis of medical conditions, lifestyle changes leading to health concerns, public health initiatives aimed at prevention and treatment, and regulatory approvals facilitating the availability of healthcare products and services.
The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period is driven by various factors, including the adoption of personalized medicine, advancements in nutritional interventions, the integration of digital health platforms, initiatives focused on patient education and empowerment, and global health efforts. Major trends expected during this period include the rise of personalized therapies, the emergence of novel drug classes, the integration of digital health solutions, collaborative research initiatives, and continued investment in research and development.
The anticipated increase in malnutrition is poised to drive the growth of the sarcopenia treatment market in the future. Malnutrition encompasses deficiencies, excesses, or imbalances in an individual's intake of energy and nutrients, including both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment plays a crucial role in addressing the concurrent conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, with the aim of enhancing muscle mass, strength, and overall nutritional status. For instance, a report published by the World Health Organization (WHO) in December 2023 highlighted malnutrition as a significant global health challenge, with an estimated 462 million underweight individuals and 149 million children under 5 experiencing stunting in 2022. Consequently, the surge in malnutrition acts as a driving force behind the growth of the sarcopenia treatment market.
Major companies in the sarcopenia treatment market are intensifying their focus on developing multiple advanced clinical studies to enhance treatment options. A clinical study involves a systematic investigation conducted on human subjects to assess the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, disclosed the authorization from the Food and Drug Administration (FDA) to commence the SARA-31 Phase 3 study in sarcopenia. This study aims to assess the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients at risk of motor disability. Representing a significant advancement in technological and pharmaceutical treatment modalities, this study offers potential benefits in terms of efficacy and safety for severe sarcopenic patients. Notably, it marks the first-ever Phase 3 study in sarcopenia to receive FDA authorization. The study will involve approximately 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoints will include the evaluation of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.
In October 2021, Rejuveron Life Sciences AG, a biotechnology company headquartered in Switzerland, completed the acquisition of Rejuvenate Biomed NV for $16.99 million. This strategic move aims to expedite the clinical advancement of Rejuvenate's primary candidate, RJx-01, targeting both acute and chronic sarcopenia. Rejuvenate Biomed NV, based in Belgium, is a clinical-stage company committed to the exploration and creation of therapies aimed at postponing the onset of age-related illnesses, including sarcopenia.
Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill
North America was the largest region in the sarcopenia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the sarcopenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The sarcopenia treatment market consists of revenues earned by entities by providing nutritional therapy, combination therapy, and muscle strength. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcopenia market also includes sales of muscle stimulators, orthopedic braces and supports, joint replacement implants, anabolic agents, and more. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sarcopenia Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on sarcopenia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for sarcopenia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcopenia treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.